News
-
Tirzepatide Constipation: How Long It Lasts
Tirzepatide constipation is common, especially in the first weeks and after dose increases. It often eases as treatment stabilizes, while severe or persistent symptoms need a clinician’s attention.
-
BPC-157 for Tendonitis: What the Evidence Shows
The tendon case for BPC-157 comes from cells and rats, not randomized human trials. Here is what those studies can tell us, what they cannot, and why rehabilitation still matters.
-
Is NAD a Peptide? What NAD+ Actually Is
NAD+ is a dinucleotide coenzyme, not a peptide. Its chemistry, cellular jobs, and evidence are different from the peptide therapies it often appears beside.
-
Is Tirzepatide FDA Approved? Not When Compounded
Tirzepatide has branded approvals under Mounjaro and Zepbound. A compounded preparation is different from an FDA-approved product: the formulation offered here is not FDA-approved.
-
Liraglutide vs Semaglutide: A Clear Comparison
Both are GLP-1 medicines, but liraglutide is usually injected daily and semaglutide weekly. Head-to-head trials show why the treatment goal and dose matter as much as the molecule.
-
Peptides for Muscle Growth: Evidence and Limits
Prescription GH-axis peptides can change hormone levels and, in selected patients, body composition. Human evidence does not show that they produce hypertrophy or greater strength in healthy trained adults.
-
Semaglutide Constipation: What Helps
Semaglutide constipation is common during initiation and dose escalation. It usually eases, but it can last longer than other stomach side effects and deserves a clear plan with the prescriber.
-
Sermorelin for Women: Evidence and Menopause
Sermorelin can raise growth-hormone output in women when the pituitary responds, but female-specific trials are small and mostly use related GHRH compounds. It is not menopause hormone therapy, and the evidence does not show reliable gains in sleep, libido or lean mass for women.
-
Tirzepatide Long-Term Side Effects: 3-Year Data
Three-year weight-management data and four-year cardiovascular data have not revealed a new late safety signal. They also do not tell us what decades of exposure will look like.
-
What Happens When You Stop Taking Tirzepatide?
Appetite suppression fades as tirzepatide clears, and weight regain is common but neither immediate nor inevitable. SURMOUNT-4 shows the difference between stopping and continuing over one year.
-
Epitalon Dosage: How a Prescriber Decides
Published evidence does not establish a standard dose. One small human AEDG study used 0.5 mg daily under the tongue for 20 days; injection-cycle numbers often come from animal work or studies of a different pineal extract.
-
How to Store Peptides: Fridge, Freezer, and Travel
Reconstituted peptide vials are commonly refrigerated at 2–8 °C, but the pharmacy label and beyond-use date always control. Lyophilized powders and commercial pens may have different limits.
-
Oral BPC-157: Do Capsules Work?
Oral activity has been reported in rat gut models, but capsules have not been tested in human trials and their absorption in people has not been measured. A capsule label cannot close that evidence gap.
-
PT-141 Side Effects: What the Trials Found
PT-141 most often causes nausea, flushing, headache, and injection-site reactions. The safety questions that change screening are blood-pressure effects, skin darkening, and how little modern evidence exists for men.
-
Best HGH Peptides: A Best-Fit Comparison
The best HGH peptides are not a strongest-to-weakest ranking. The useful comparison is which receptor they use, how long they act, and whether the evidence matches the reason a clinician is considering them.
-
How Often Do You Inject Peptides?
Injection frequency can range from nightly to once weekly because each peptide has a different half-life, mechanism, and formulation. The prescription label for the exact vial sets the schedule.
-
Peptides for Autoimmune Disease: The Evidence
Thymosin Alpha-1 has meaningful human immune-modulation research, while KPV remains mostly a cell-and-animal finding; neither has clinical evidence that makes it an autoimmune treatment.
-
Peptides for Insulin Resistance: Evidence
The evidence runs from large clinical trials for semaglutide and tirzepatide to animal and observational research for MOTS-c. Those are not interchangeable levels of certainty.
-
Telehealth Peptide Therapy: How the Process Works
Telehealth peptide therapy is a prescription-based clinical service: medical intake, provider review, pharmacy dispensing, and follow-up. The important distinction is accountability at every handoff, not simply ordering a vial online.
-
Does Semaglutide Cause Muscle Loss?
Semaglutide-related weight loss can include a drop in lean mass, but DXA lean mass is not the same as skeletal muscle. STEP 1 found fat fell faster than lean tissue, improving lean mass as a share of body weight.
Page 12 of 18 · 344 articles